NCT00727506 - BIBW 2992 (Afatinib) With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant Glioma | Biotech Hunter

Enrollment

151

Participants

Timeline

Start Date

July 14, 2008

Primary Completion Date

May 12, 2011

Study Completion Date

May 25, 2016

Conditions

Glioma

Interventions

DRUG

BIBW 2992

BIBW 2992 once daily

DRUG

TMZ

TMZ 21/28

DRUG

BIBW 2992 plus TMZ

BIBW 2992 once daily plus TMZ 21/28 days

Trial Locations (28)

Unknown

1200.36.0016 Boehringer Ingelheim Investigational Site, Birmingham

1200.36.0012 Boehringer Ingelheim Investigational Site, Phoenix

1200.36.0005 Boehringer Ingelheim Investigational Site, Duarte

1200.36.0014 Boehringer Ingelheim Investigational Site, Los Angeles

1200.36.0019 Boehringer Ingelheim Investigational Site, Orlando

1200.36.0023 Boehringer Ingelheim Investigational Site, Atlanta

1200.36.0008 Boehringer Ingelheim Investigational Site, Louisville

1200.36.0002 Boehringer Ingelheim Investigational Site, Boston

1200.36.0003 Boehringer Ingelheim Investigational Site, Detroit

1200.36.0009 Boehringer Ingelheim Investigational Site, New York

1200.36.0001 Boehringer Ingelheim Investigational Site, Durham

1200.36.0007 Boehringer Ingelheim Investigational Site, Charleston

1200.36.0020 Boehringer Ingelheim Investigational Site, Memphis

1200.36.0017 Boehringer Ingelheim Investigational Site, Dallas

1200.36.0010 Boehringer Ingelheim Investigational Site, Houston

1200.36.0011 Boehringer Ingelheim Investigational Site, Charlottesville

1200.36.0022 Boehringer Ingelheim Investigational Site, Seattle

1200.36.1005 Boehringer Ingelheim Investigational Site, Calgary

1200.36.1010 Boehringer Ingelheim Investigational Site, Winnipeg

1200.36.1009 Boehringer Ingelheim Investigational Site, Moncton

1200.36.1011 Boehringer Ingelheim Investigational Site, Halifax

1200.36.1008 Boehringer Ingelheim Investigational Site, Hamilton

1200.36.1001 Boehringer Ingelheim Investigational Site, Kingston

1200.36.1003 Boehringer Ingelheim Investigational Site, Toronto

1200.36.1004 Boehringer Ingelheim Investigational Site, Toronto

1200.36.1007 Boehringer Ingelheim Investigational Site, Fleurimont

1200.36.1002 Boehringer Ingelheim Investigational Site, Montreal

1200.36.1006 Boehringer Ingelheim Investigational Site, Québec